Navigation Links
U-M Medical School and MedImmune join forces to accelerate search for new therapies
Date:11/21/2011

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects.

The three-year strategic collaboration will bring scientists from one of the nation's top medical research institutions together with scientists from one of the world's leading developers of biologic therapies.

UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

This type of translational and pre-clinical research is designed to identify and confirm the specific molecules and genes involved in causing disease, and potential molecules and cell-based therapies to treat or prevent them.

"We are thrilled to partner with MedImmune in a collaborative and creative way to bring new innovations to market," says Steven Kunkel, Ph.D., senior associate dean for research at the U-M Medical School and Endowed Professor of Pathology Research. "This strategic partnership, one of the first of its kind for our institution, speaks to our desire to collaborate with industry to accelerate translation of U-M's cutting-edge research to impact patients."

The new agreement goes beyond the traditional type of academic-industry research relationship, in which companies fund projects such as clinical trials, or license patents on discoveries made by university scientists and develop them on their own. In this new type of agreement, scientists from medical schools and industry collaborate closely on projects while also preserving academic freedom, research integrity and both sides' rights to intellectual property for discoveries.

"This new horizon in industry-academic partnership ultimately benefits patients, who demand new and better options for treating diseases," says Norman Greenberg, Ph.D., MedImmune's Vice President for Oncology Research and Development. "New types of partnerships between academic biomedical powerhouses such as Michigan, and industry leaders such as MedImmune, are needed to accelerate the search for those options."

The initial focus on oncology leverages the strength of the U-M Comprehensive Cancer Center.

U-M cancer scientists, led by center director Max Wicha, M.D., have won more research grant dollars from the National Cancer Institute than researchers at any other academic medical center.

"Working with MedImmune to explore new ways to target treatments is a natural progression of the basic scientific discoveries that our teams have made in the last decade," says Wicha, who is also the Distinguished Professor of Oncology in the Department of Internal Medicine at the U-M Medical School.


'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. New smart material could help tap medical potential of tissue-penetrating light
2. CDC and Prevention awards Mayo Clinic an international medical education grant
3. New international health survey of sicker adults: Those with a medical home fare better
4. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
5. University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients
6. Teen Pot Use Unaffected by Medical Marijuana Law: Study
7. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
8. Diagnostic physicians at increased risk for medical malpractice claims due to communication failures
9. Medical researchers ID potential new drug target that could stop debilitating effects of MS
10. Ghost Writing Persists in Major Medical Journals
11. Harvard Medical School and EPFL launch program targeting neurological disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: